<DOC>
	<DOC>NCT02024334</DOC>
	<brief_summary>A randomized double blind clinical trial to assess efficacy of leflunomide in treatment of refractory juvenile idiopathic arthritis. Patients are randomly divided into two groups. In group 1 leflunomide and in group 2 placebos will be added to conventional treatment for three months. therapeutic responses will be evaluated by ACRpedi (American College of Rheumatology Pediatric) scores every 4 weeks.</brief_summary>
	<brief_title>Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>30 Patients(2-19 y) are randomly divided into two groups. In group 1 leflunomide will be added to conventional treatment, 5-20 mg daily based on weight. In group 2 placebo will be prescribed as same as leflunomide. The course of treatment is 3 months. Every 4 weeks ACRped 30, 50, 70 should be determined to evaluate therapeutic response. Side effects of treatment will be assessed by physical examination and lab tests every 4 weeks.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>JIA based on ACR criteria age between 2 19 y polyarticular, oligoarticular(&gt; or = 3 active joints) or extended oligoarticular subtypes resistance to conventional treatment pregnancy malignancy severe active infection other rheumatic diseases or overlap ALT(Alanine transaminase) or bilirubin &gt; 3 folds IVIG (Intravenous immunoglobulin) treatment during last 2 weeks biologic agents during last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>JIA</keyword>
	<keyword>LEFLUNOMIDE</keyword>
	<keyword>EFFICACY</keyword>
</DOC>